Developments in combination chemotheraphy for colorectal cancer

Matthew M.P. Goetz, Axel Grothey

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

In the 5 years, major advances have occurred in the treatment of colorectal cancer. Following a period of over 30 years in which 5-fluorouracil was the only proven treatment for colorectal cancer, survival for patients with metastatic colorectal cancer has nearly doubled following the introduction of irinotecan (Campto®, Aventis) and oxaliplatin (Eloxatin®, Sonofi-Synthelabo). Furthermore, recent studies have demonstrated additional improvements in response and survival when combination chemotherapy drugs are administered with biologic agents that target angiogenesis and tumor growth pathways. The benefit of these newer drugs is now being realized in the adjuvant setting, where the addition of oxaliplatin to infusional 5-fluorouracil/leucovrin has led to improvements in disease-free survival. Further adjuvant studies are testing the benefit of the addition of biologic therapies to oxaliplatin and irinotecan-based combination chemotherapy.

Original languageEnglish (US)
Pages (from-to)627-637
Number of pages11
JournalExpert review of anticancer therapy
Volume4
Issue number4
DOIs
StatePublished - Aug 2004

Keywords

  • 5-fluorouracil
  • Bevacizumab
  • Capecitabine
  • Cetuximab
  • Chemotherapy
  • Colorectal cancer
  • Irinotecan
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Developments in combination chemotheraphy for colorectal cancer'. Together they form a unique fingerprint.

  • Cite this